FDA Approves First 14-Day Hemophilia B Treatment

March 5, 2016

Note: The following is an edited form of a press release from the FDA . The original form of the release can be read here. The U.S. Food and Drug Administration approved on Friday, March 4, Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the […]

FDA Accepts CSL Behring’s Application for New Long-Acting Hemophilia B Product

February 4, 2015

This is an edited version of a press release from CSL Behring. To read the full release, please click here. ____________________  CSL Behring announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant […]

Baxter Reports Success in Long-Acting Hemophilia Product

August 23, 2014

This article was originally published in Reuters on August 21, 2014. Click here to read it in its entirety. ______________________ Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study. The experimental drug, BAX 855, was being tested as a preventive therapy […]

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.